Frontlight ResearchEarly access
TerminatedPhase 1/2
NEPHSTROM for Diabetic Kidney Disease
Key facts
- Who runs it
- Mario Negri Institute for Pharmacological Research
- Where
- Ireland, Italy, and United Kingdom4 sites in 3 countriesChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 1/2
- People taking part
- 29 people enrolled
- Started
- 11 Dec 2017
- Ended
- 3 Jan 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Mesenchymal Stromal Cells
- Placebo
- Record updated
- 29 November 2024
- Why it stopped
- IMP NEPHSTROM ORBECEL-M is expired and additional extension is not feasible. Low recruitment rate at Birmingham center.
Who can take part
- Age
- 40 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (28)Hide the full registry criteria
Who can take part
- Male and female ≥ 40 years and <85 years old.
- T2D for 3 or more years under a clinician with mandated responsibility for management of the patients to national guidelines
- Urinary albumin excretion (UAE) ≥ 60 µg/min (in a 24 hour urine collection) and urine albumin-to-creatinine ratio (UACR) ≥ 88 mg/g (≥ 10 mg/mmol) (in a spot morning urine collection)
- Estimated GFR (eGFR) 30-50 ml/min/1.73 m\^2 by the CKD-EPI equation on 2 or more consecutive measurements at least 30 days apart within the past 6 months
- A documented decline of eGFR of ≥ -10ml/min/1.73 m\^2 over the past 3 years or documented rate of eGFR decline of ≥ -5 ml/min/1.73 m\^2 year based on 3 or more consecutive readings at least 90 days apart in the past 18 months
- Lack of suspicion of renal diagnosis other than DKD
- Willing and able to provide written informed consent
Who cannot take part
- Current resting systolic BP ≥ 150 mmHg and current resting diastolic BP ≥ 90 mmHg in a clinical setting, despite treatment with 3 hypertensive agents of different classes (including one diuretic), measured in a quiet environment with morning medications already taken
- Increase the dose of an anti-hypertensive agent by ≥ 100% of the previous dose within the past 3 months
- Increase the dose of a hypoglycaemic agent by ≥ 100% of the previous dose within the past 3 months
- Cardiovascular events (myocardial infarction, stroke or acute limb ischemia) within 6 months prior to enrolment
- Current or history within 6 months prior to enrolment of NYHA class III or IV heart failure
- Other concomitant disease or conditions in the opinion of the investigator that are likely to pose risk to the patient and that would render the patient unsuitable for participation or that could impair patient safety or ability to participate in the study, such as active malignancy
- Positive screening test for clinically significant anti-HLA antibodies. An initial antibody screening with Luminex® multi-antigen beads to detect class I and class II MHC antibodies followed by a Luminex single antigen bead assay to determine the specificity of any antibody detected. Potential study subjects with positive screening for any clinically significant anti-HLA antibody will be excluded and will not be eligible to participate in the NEPHSTROM clinical study (MFI>1500)
- Participation in other investigational medicinal product (IMP) trials within 30 days before the inclusion or concurrent to this study (18 month follow-up)
- Chronic lung or liver disease
- Irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%
- History or presence of any medical condition or disease which, in the opinion of the Investigator may place the participant at unacceptable risk for study participation
- Current HbA1c > 75 mmol/mol (> 9%)
- Current fasting total cholesterol > 7 mmol/l
- Current fasting total triglycerides > 3.5 mmol/l
- Childbearing potential without use of effective acceptable methods of contraception. Women of childbearing potential can only be included in the study if a pregnancy test is negative at the screening visit (V1) and at baseline visit (V2) if they agree to use adequate contraception. Adequate contraception is defined as any combination of at least two effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices). Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate) or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL or have had surgical treatment such as bilateral tubal ligation, bilateral oophorectomy, or hysterectomy
- Initiation of a new anti-hypertensive agent within the past 6 months
- Initiation of a new hypoglycaemic agent within the past 6 months
- Initiation of a new lipid lowering agent within the past 6 months; Other exclusion criteria:
- Pregnancy or lactating
- Inability to understand the potential risks and benefits of the study
- Legal incapacity
Where is this trial?
It has sites in 3 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study will investigate, primarily, the safety, feasibility and tolerability and, secondarily, the preliminary efficacy of an allogeneic bone marrow-derived Mesenchymal Stromal Cell (MSC) therapy (ORBCEL-M) in study subjects with type 2 diabetes (T2D) and progressive diabetic kidney disease (DKD).
The 2 groups in the trial
- Bone marrow-derived Mesenchymal Stromal CellsTreatment being tested
Treatment: Mesenchymal Stromal Cells
- Cryostor CS10Placebo, for comparison
Treatment: Placebo
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)
- Publications
- MSC therapy for diabetic kidney disease and nephrotic syndrome.Nature reviews. Nephrology, 2023
- Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).Journal of the American Society of Nephrology : JASN, 2023
- Record updated
- 29 November 2024